CerraCap Ventures Invests in Nephronomics for AI Kidney Disease Research

April 21, 2026
CerraCap Ventures has invested in Nephronomics, an AI bio precision medicine company developing data driven approaches to kidney disease research and drug discovery. The partnership aims to advance precision therapies using one of the largest renal datasets in the world.

CerraCap Ventures has invested in Nephronomics, an AI bio precision medicine company focused on kidney disease, announced in a press release. The investment supports Nephronomics' goal of advancing precision therapies for cardio kidney metabolic disease through large scale data analysis.

Nephronomics is building a comprehensive clinical and genomic dataset covering more than 42,000 patients from dialysis clinics across the United States. Its platform applies machine learning to identify disease subtypes, reveal causal mechanisms, and discover new therapeutic targets for chronic kidney disease.

According to the announcement, Nephronomics holds exclusive access to one of the largest renal datasets globally, which includes whole genome and longitudinal clinical data. The company plans to use this resource to develop internal drug programs and collaborate with pharmaceutical partners.

CerraCap Ventures, based in Southern California, focuses on early stage enterprise technology investments. The firm said the partnership with Nephronomics aligns with its strategy of supporting companies that apply AI to create new models for healthcare innovation.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

04/21
Dubai International Financial Centre to Become World's First AI Native Financial Hub
04/21
Sinai.ai Raises $1.45 Million Pre-Seed Funding for Interactive AI Books
04/21
Trust3 AI Integrates with Google Cloud Agentic Stack for AI Governance
04/21
Blaize and Datacomm Form Alliance to Develop AI Inference Solutions in Indonesia
04/21
Catalyx Partners with Canoga Perkins to Add Private 5G to Line Clearance System

More from: Life Sciences

04/21
Viva Biotech Highlights AI and Flow Chemistry Integration for Scalable Drug Synthesis
04/21
Castle Biosciences to Present New Data on DecisionDx-Melanoma at EADO and ACMS Meetings
04/21
VytlOne Introduces VytlAIQ Platform for 340B and Specialty Pharmacy Services
04/21
Brado AI Completes CMS Health Technology Ecosystem Pledge
04/21
WCG Acquires The Contract Network to Expand AI Site Enablement Platform

Subscribe to AI Funding Brief

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You May Also Like